126 related articles for article (PubMed ID: 11059257)
1. [New implications for mental disorders treatment: pharmacogenetic studies of dopaminergic and serotonergic neurotransmission systems].
Samochowiec J; Pełka-Wysiecka J; Rottmann M; Horodnicki J
Psychiatr Pol; 2000; 34(4):561-76. PubMed ID: 11059257
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
3. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.
Wood MD; Wren PB
Prog Brain Res; 2008; 172():213-30. PubMed ID: 18772035
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic receptors for dopamine, histamine, and serotonin.
Feuerstein TJ
Handb Exp Pharmacol; 2008; (184):289-338. PubMed ID: 18064418
[TBL] [Abstract][Full Text] [Related]
5. [Genetic background of ADHD: population studies, genes of the catecholamine system].
Słopién A; Dmitrzak-Weglarz M; Rybakowski F; Rajewski A; Hauser J
Psychiatr Pol; 2006; 40(1):19-31. PubMed ID: 16756025
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenetics and tailored drug treatment in schizophrenia].
Andreassen OA; Steen VM
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
[TBL] [Abstract][Full Text] [Related]
7. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric pharmacogenomics in pediatric psychopharmacology.
Wall CA; Croarkin PE; Swintak C; Koplin BA
Child Adolesc Psychiatr Clin N Am; 2012 Oct; 21(4):773-88. PubMed ID: 23040901
[TBL] [Abstract][Full Text] [Related]
9. [Receptor polymorphism and response to treatment in schizophrenia].
Szekeres G; Janka Z
Orv Hetil; 2002 Sep; 143(35):2027-33. PubMed ID: 12387196
[TBL] [Abstract][Full Text] [Related]
10. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
Miczek KA; Fish EW; De Bold JF; De Almeida RM
Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
[TBL] [Abstract][Full Text] [Related]
11. The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings.
O'Neill BV; Croft RJ; Nathan PJ
Hum Psychopharmacol; 2008 Jul; 23(5):355-70. PubMed ID: 18421800
[TBL] [Abstract][Full Text] [Related]
12. What do we know about serotonin?
Jonnakuty C; Gragnoli C
J Cell Physiol; 2008 Nov; 217(2):301-6. PubMed ID: 18651566
[TBL] [Abstract][Full Text] [Related]
13. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
14. Genomic influences on schizophrenia-related neurotransmitter systems.
Keltner NL
J Nurs Scholarsh; 2005; 37(4):322-8. PubMed ID: 16396404
[TBL] [Abstract][Full Text] [Related]
15. [Increased knowledge of dopamine receptors results in better drugs in the treatment of neurologic and psychological disorders].
Hall H
Lakartidningen; 1991 Aug; 88(35):2761-5. PubMed ID: 1895826
[No Abstract] [Full Text] [Related]
16. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).
Oades RD
Prog Brain Res; 2008; 172():543-65. PubMed ID: 18772050
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics. Promise and potential in child and adolescent psychiatry.
Anderson GM; Cook EH
Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):23-42, viii. PubMed ID: 10674189
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives.
Gesteira A; Barros F; Martín A; Pérez V; Cortés A; Baiget M; Carracedo A
Actas Esp Psiquiatr; 2010; 38(5):301-16. PubMed ID: 21117005
[TBL] [Abstract][Full Text] [Related]
19. Functional polymorphisms in dopamine and serotonin pathway genes.
D'Souza UM; Craig IW
Hum Mutat; 2006 Jan; 27(1):1-13. PubMed ID: 16320307
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
Camilleri M
Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():40-5. PubMed ID: 17620087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
